Ann M. Leen
CIK 1763026 · Chief Scientific Officer · last filed 2023-02-03
Ann M. Leen is a Chief Scientific Officer who has filed 12 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for ALVR, was dated Feb 3, 2023. Across all open-market trades the lifetime net is −$5.4M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ALVR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 200
JACKSONVILLE, FL 32202
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Chief Scientific Officer | 101,714 | $9.81 | $997.8K | -$5.39M | 12 | 2023-02-03 |
Recent Filings
12 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-02-03 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +81,006 | $0 | EDGAR |
| 2022-08-17 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +15,000 | $0 | EDGAR |
| 2021-11-16 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −20,988 | -$465.6K | EDGAR |
| 2021-05-10 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −150,000 | -$3.41M | EDGAR |
| 2021-03-18 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −3,025 | -$90.8K | EDGAR |
| 2021-03-03 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −9,518 | -$368.3K | EDGAR |
| 2021-02-23 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −17,446 | -$723.6K | EDGAR |
| 2021-02-19 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −2,700 | -$110.2K | EDGAR |
| 2021-02-18 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Sell (S) | −5,336 | -$220.2K | EDGAR |
| 2021-01-21 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Mixed | +28,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.